destabilization of the mAb in the presence of 10 mM DPA, or by the related quinolinic acid (QA, 25 pyridine-2,3-dicarboxylic acid). However, fluorescence spectrophotometry did reveal localized 26 (aromatic) conformational changes to the mAb attributed to DPA, dependent on the salt form. While 27 precise mechanisms of action remain to be identified, our preliminary data suggest that these DPA 28 salts are worthy of further investigation as novel ionic excipient for biologics formulation. the cellular protoplast is surrounded by a thick layer of modified peptidoglycan, referred to as the 39 cortex, which probably mechanically enforces the reduced water content of the spore core (Paredes-40 Sabja et al., 2011). Second, the spore core environment is highly mineralised with calcium and other 41 divalent metal ions, which are chelated with pyridine-2,6-dicarboxylic acid (dipicolinic acid or DPA). 42
The latter is uniquely associated with bacterial spores in nature, comprising approximately 10-15 % of 43 the dry weight of spores (Paredes-Sabja et al., 2011) . While the precise function of DPA in spores has 44 not definitively been elucidated, it clearly has a role in the maintenance of spore dormancy i.e. mutant 45 strains of Bacillus that lack enzymes involved in DPA synthesis are unstable and lyse before maturity 46 (Paredes-Sabja et al., 2011; Setlow, 2014) . Similarly, the induced release of DPA from the spore core 47 -whether achieved via nutrient induced germination, or by exposure of spores to certain cationic 48 surfactants or extremely high pressures -results in the loss of spore dormancy and resistance 49
properties (Setlow, 2014) . 50
One potential role for DPA at the molecular level is to promote the stability of essential spore-core 51 located proteins during dormancy and spore germination, perhaps by minimising thermal-induced 52 motion and the likelihood of denaturation and aggregation. Given the apparent protective role of DPA 53 in spores, we conjectured whether it would be able to fulfil a similar function as an excipient to 54 pharmaceutical proteins of interest. The most commonly used pharmaceutical excipients include 55 amino acids, polyols, salts, sugars, and surfactants (Manikwar et al., 2013) . However, considerable 56 effort has been made in recent years to identify and develop new excipients that mitigate the physical 57 and chemical instability of biological drugs (Du and Klibanov, 2011; Lee et al., 2014) . The use of 58 novel Arg salts, for example, including equimolar formulations with glutamic acid, have been 59
reported to exert synergistic effects in terms of reducing intermolecular attractions and aggregation, 60 compared to Arg.HCl alone (Kheddo et al., 2016; Kheddo et al., 2014) . 61
Here we report on the use of DPA, and its quinolinic acid (QA) analogue, as novel excipients that 62 may have potential in mAb formulation. This class of biopharmaceutical is of particular interest since 63 subcutaneous injections of mAbs comprise low volume (<1.5 ml) high protein concentration (>100 64 mg/ml) formulations. Such conditions promote aggregation, reversible self-association and particulate 65 formation, with the resultant solubility and viscosity issues presenting considerable challenges to 66 large-scale manufacture, product stability and delivery (Shire et al., 2004) . 67 68
Materials and Methods 69

Chemicals and reagents 70
All reagents were purchased at > 98% purity. 2,3-Pyridinedicarboxylic acid (quinolinic acid or QA), 71 2,6-pyridinedicarboxylic acid (DPA), Bradford Reagent, calcium hydroxide, lysozyme and 72 Scienceware® Aquet® liquid detergent were purchased from Sigma-Aldrich (Dorset, UK). Arg, Arg 73 hydrochloride, histidine, histidine hydrochloride, and sodium chloride were acquired from J. T. /mg and pI 9.04. MAbs A, B and C were 80 achieve the desired QA and DPA concentrations. Buffers and MilliQ water were degassed by 109 sonication, whereas protein samples were degassed using a degassing station (TA Instruments). 110
Lysozyme was used as a reference protein. 900 µL of each sample and buffer were pipetted into a 96-111 deepwell plate and samples were heated from 25-90°C using a rate of 2°C/min and an equilibration 112 time of 600 s using a NanoDSC differential scanning calorimeter (TA Instruments). Data analysis was 113 performed in NanoAnalyze 3.6.0 software (TA Instruments). DSC curves were fitted using a two-state 114 model of three independent domains to determine the melting temperature (T m (ºC)) and enthalpy and the absorbance measured at 450 nm using a Cary 100 UV-Vis spectrophotometer equipped with a 146 multicell Peltier and circulating water bath. As samples were cooled from 25°C to 4°C the absorbance 147 was read incrementally at 0.5°C intervals. 148 149
Viscosity measurements 150
A 1 mL syringe was filled with mAb A at different concentrations (45, 75, 100 and 150 mg/mL) in 25 151 mM His, 120 mM NaCl, pH 6 containing different excipients: 10 mM CaCl 2 .2H 2 O; 10 mM Ca(OH) 2 , 152 10 mM QA, 10 mM Ca(OH) 2 , 10 mM DPA; 20 mM Arg.HCl; 20 mM Arg, 10 mM QA; and 20 mM 153 Arg, 10 mM DPA. Sample viscosity was measured using an m-VROC TM viscometer (Rheosense, Inc., 154
San Ramon, CA, USA). The chip was flushed with each sample for 10 s at a shear rate of 6000 s -1 and 155 23°C, followed by a second injection for 30 s at a shear rate of 6000 s -1 at 23°C. The viscosity value 156 measured during the second injection was considered to be more accurate. Between each sample 157 measurement, the chip was flushed at a flow rate of 750 µL min -1 for 60 s in a sequential manner with 158 the following solutions: 1% tergazyme, 1% aquet, filtered MilliQ water and sample buffer. 159 160
Analysis of protein aggregation and fragmentation using High Performance Size Exclusion 161
Chromatography (HPSEC) 162
All samples were stored in 3 mL clear vials at 5 and 40 ºC. HPSEC analysis was performed on an 163
Agilent HPLC system with a TSK-Gel G3000 column to assess monomer profile of the samples after 164 different time points: 0, 4 weeks (at 5 ºC and 40 ºC) and 12 weeks (at 5 ºC). The HPLC system was 165 equipped with a multiple wavelength UV detector set at 280 nm wavelength. The samples were 166 diluted to a concentration of 10 mg/mL using phosphate buffered saline (PBS) before loading into the 167 column at an injection volume of 25 µL. The mobile phase used was 0.1 M sodium phosphate dibasic 168 anhydrous 0.1 M sodium sulphate pH 6.8. 169 Trp is fully exposed to the aqueous environment). In this study, the maximum emission wavelength 197 To exploit the broader applicability of DPA as a pharmaceutical excipient, we have further 256 investigated the stability of two additional mAbs (mAb B and mAb C) formulated with DPA. DPA 257 concentrations were increased up to 100 mM (200 mM Arg -100 mM DPA) to understand the effects 258 of higher excipient concentration on protein stability. Arg salts were selected over Ca 2+ salts due to 259 the limited aqueous solubility of Ca-DPA. Arg.HCl was used as a positive control (at 200 mM). After 260 4 weeks at 40°C, aggregation was significantly reduced for both mAbs B and C for formulations 261 containing either Arg.HCl or Arg-DPA, while there was a slight increase in fragmentation. At 5°C 262 there was no increase in aggregation or fragmentation even after 12 weeks (Table 2) . 
Discussion 271
The stability of protein-based liquid formulations is of significant interest to the pharmaceutical 272 industry, since the physical instability of biopharmaceuticals can undermine their safety and efficacy. 273 This is particularly relevant at the high protein concentrations required typically for therapeutic 274 administration, where non-specific aggregation is more likely to occur. As such, excipient molecules, 275 such as Arg, are added to biopharmaceutical drugs in order to supress aggregation, minimise phase 276 separation, reduce viscosity and increase the shelf life of the product. 277
The underlying mechanisms associated with Arg-mediated suppression of aggregation have not been and it may be necessary to identify salt forms that facilitate mAb formulation studies at concentrations 295 employed typically in current mAb formulations i.e. 50 to 150 mM. 296
In terms of potential mechanisms of action, structural perturbation of mAb A -in the presence of DPA 297 salts in particular -was confined to localised mobilisation of aromatic side chains, at least as adjudged 298 from intrinsic fluorescence analyses. More general conformational changes involving gross changes 299 to the protein secondary structural elements or surface hydrophobicity were not detected using 300 
Conclusion 315
In conclusion, this work introduces a new class of organic acids -inspired by their association with 316 bacterial spores -as novel excipients in the context of protein formulation. We suggest that future 317 work, at least in the medium term, should aim to elucidate further the mode of action of DPA and QA 318 salts on mAb stability, characterise further the effects on mAb stability, and identify salts that are 319 suitable for scaling up during manufacture. 
